Biotech M&A on Track for Best Year Since Pre-Covid Era

Biotech mergers and acquisitions are experiencing a strong start in 2026, poised for their best year since before the Covid-19 pandemic, driven by looming patent cliffs, buoyant public markets, and Big Pharma's pipeline expansion efforts.